ClinicalTrials.gg
CompletedNCT05355935Updated Mar 27, 2023

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

A Phase 1 interventional study of Brensocatib and Moxifloxacin in Healthy Volunteer, sponsored by Insmed Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Insmed Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2022, 4 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study has 2 Parts: The primary purpose of Part 1 is to determine the supratherapeutic dose of brensocatib to be used in Part 2 of the study.

The primary purpose of Part 2 is to assess brensocatib's potential for prolonging the QT interval.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Brensocatib
  • INS1007
03

In context

Lead sponsor

Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) between 18.0 and 32.0 kilogram per square metre (kg/m\^2), inclusive, and a total body weight greater than or equal to 50 kilograms (kg)
  2. Females will not be pregnant or lactating, and females of and males will agree to use
  3. Able to comprehend and willing to sign an form (ICF) and to abide by the study restrictions
  4. Able to swallow tablets

Exclusion criteria

Exclusion Criteria:

  1. History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee)
  2. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs
  3. interval >430 ms for males and >440 ms for females or QRS >120 ms
  4. A history of additional risk factors for torsade de pointes (eg, heart failure, hypokalemia, or family history of long QT syndrome)
  5. Positive serology test results for panel and antibody and/or reactive 1/2 test
  6. Administration of a coronavirus disease 2019 (COVID-19) vaccine in the past 14 days prior to dosing
  7. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee)
  8. Use or intend to use any prescription medications/products within 14 days prior to dosing, unless deemed acceptable by the investigator (or designee)
  9. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to check-in, unless deemed acceptable by the investigator (or designee)
  10. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to check-in, unless deemed acceptable by the investigator (or designee)
  11. Use or intend to use any medications that may increase QT interval within 14 days prior to check-in
  12. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days prior to dosing
  13. Have previously completed or withdrawn from this study or any other study investigating brensocatib, and have previously received brensocatib
  14. Alcohol consumption of >14 units per week for males and >7 units for females. One unit of alcohol equals 12 ounce (oz) (360 milliliter [mL]) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine
  15. Consumption of caffeine-containing products within 48 hours prior to check-in, unless deemed acceptable by the investigator (or designee)
  16. History of chemical abuse, illicit substance, or marijuana use within 1 year prior to check-in
  17. Use of tobacco- or nicotine-containing products within 3 months prior to check-in
  18. Receipt of blood products within 2 months prior to check-in
  19. Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or from 6 weeks prior to screening
  20. Poor peripheral venous access
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Part 1: Treatment Dose 1

    Participants (in a 3:1 ratio) will receive a single oral dose of brensocatib Dose 1 or placebo, once on Day 1.

    Drug: Brensocatib · Drug: Placebo

  • Experimental
    Part 1: Treatment Dose 2

    Participants (in a 3:1 ratio) will receive a single oral dose of brensocatib Dose 2 or placebo, once on Day 1.

    Drug: Brensocatib · Drug: Placebo

  • Experimental
    Part 2

    Participants will be randomized to 1 of 4 treatment sequences (ABCD, BDAC, CADB, DCBA).

    Drug: Brensocatib · Drug: Moxifloxacin · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants who Experienced at least one Treatment-Emergent Adverse Event (TEAE) as Assessed by Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)

    Time frame: Up to Day 7

  2. Part 2: Placebo- and Baseline-Corrected QTcF (ΔΔQTcF)

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

Secondary outcomes

  1. Parts 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Brensocatib

    Time frame: Part 1: Pre-dose and at multiple timepoints post-dose on Days 1 to 4; Part 2: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

  2. Parts 1 and 2: Time to Maximum Observed Plasma Concentration (Tmax) of Brensocatib

    Time frame: Part 1: Pre-dose and at multiple timepoints post-dose on Days 1 to 4; Part 2: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

  3. Parts 1 and 2: Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUCtlast) of Brensocatib

    Time frame: Part 1: Pre-dose and at multiple timepoints post-dose on Days 1 to 4; Part 2: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

  4. Parts 1 and 2: AUC From Time Zero Extrapolated to Infinity (AUC∞) of Brensocatib

    Time frame: Part 1: Pre-dose and at multiple timepoints post-dose on Days 1 to 4; Part 2: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

  5. Parts 1 and 2: Elimination Half-Life (t1/2) of Brensocatib

    Time frame: Part 1: Pre-dose and at multiple timepoints post-dose on Days 1 to 4; Part 2: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

  6. Parts 1 and 2: Total Clearance of Brensocatib Following Extravascular Administration (CL/F)

    Time frame: Part 1: Pre-dose and at multiple timepoints post-dose on Days 1 to 4; Part 2: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

  7. Parts 1 and 2: Volume of Distribution of Brensocatib Following Extravascular Administration (Vz/F)

    Time frame: Part 1: Pre-dose and at multiple timepoints post-dose on Days 1 to 4; Part 2: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

  8. Parts 2: Change From Baseline in QTcF (ΔQTcF) Interval

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

  9. Part 2: Number of Participants With Categorical Outliers for ECG Parameters: HR, PR, QRS, and QTcF

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

  10. Part 2: Number of Participants who Experienced at least one TEAE

    Time frame: 7 days after the last dose (up to 35 days)

07

Study locations

1 site
  • USA001
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Oct 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
May 2, 2022
StartActual
Apr 27, 2022
Primary completionActual
Oct 7, 2022
CompletionActual
Oct 7, 2022
Last update
Mar 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05355935
Responsible party
Sponsor
First posted
May 2, 2022
Start date
Apr 27, 2022
Primary completion
Oct 7, 2022
Completion
Oct 7, 2022
Last update
Mar 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brensocatib

Start the discussion